Cybin (CYBN) Stock Research

CYBN

· CYBN

Over a week ago

Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial

Jan 8, 10:57 AM

Three new option listings and four option delistings on January 5th

Jan 5, 8:30 AM

Cybin to change name, symbol

CYBN

Jan 5, 7:39 AM

Cybin initiates at-the-market equity program of up to $100M

CYBN

Dec 30, 3:36 PM

Jefferies sees potential tailwind forming for psychedelics from marijuana shift

Dec 19, 11:04 AM

Cybin to transfer U.S. stock exchange listing to Nasdaq

Dec 18, 12:32 PM

Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial

Dec 18, 10:32 AM

Psychedelic: Clearmind reports CMND-100 dosing at Hadassah Medical Center

Dec 4, 10:55 AM

Cybin price target raised by $9 at Guggenheim, here's why

CYBN

Dec 3, 7:21 AM

Psychedelic: Clearmind reports results from first cohort in AUD trial

Nov 20, 12:00 PM

Cybin price target lowered by $25 at Canaccord, here's why

CYBN

Nov 20, 6:24 AM

Cybin price target lowered by $95 at H.C. Wainwright, here's why

CYBN

Nov 14, 11:06 AM

Psychedelic: Atai Beckley, Cybin report quarterly earnings

Nov 13, 11:26 AM

Cybin reports Q2 EPS ($1.39), consensus ($1.33)

CYBN

Nov 13, 10:49 AM

No more stories

Charts

Over a week ago

Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial

Jan 8, 10:57 AM

Three new option listings and four option delistings on January 5th

Jan 5, 8:30 AM

Cybin to change name, symbol

CYBN

Jan 5, 7:39 AM

Cybin initiates at-the-market equity program of up to $100M

CYBN

Dec 30, 3:36 PM

Jefferies sees potential tailwind forming for psychedelics from marijuana shift

Dec 19, 11:04 AM

Cybin to transfer U.S. stock exchange listing to Nasdaq

Dec 18, 12:32 PM

Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial

Dec 18, 10:32 AM

Psychedelic: Clearmind reports CMND-100 dosing at Hadassah Medical Center

Dec 4, 10:55 AM

Cybin price target raised by $9 at Guggenheim, here's why

CYBN

Dec 3, 7:21 AM

Psychedelic: Clearmind reports results from first cohort in AUD trial

Nov 20, 12:00 PM

Cybin price target lowered by $25 at Canaccord, here's why

CYBN

Nov 20, 6:24 AM

Cybin price target lowered by $95 at H.C. Wainwright, here's why

CYBN

Nov 14, 11:06 AM

Psychedelic: Atai Beckley, Cybin report quarterly earnings

Nov 13, 11:26 AM

Cybin reports Q2 EPS ($1.39), consensus ($1.33)

CYBN

Nov 13, 10:49 AM

No more stories

Company News

Charts

CYBN

· CYBN

Company News

Charts

CYBN

· CYBN